<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>PolyQ - SCA7</title>
  <link rel="shortcut icon" href="../../Images/image1.ico">
  <link rel="stylesheet" href="style_2.css">
  <link rel="stylesheet" href="highlight-js/highlightjs.css">
  <link rel="stylesheet" href="ScrollSpy.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.1/css/all.min.css" integrity="sha512-KfkfwYDsLkIlwQp6LFnl8zNdLGxu9YAA1QvwINks4PhcElQSvqcyVLLD9aMhXd13uQjoXtEKNosOWaZqXgel0g==" crossorigin="anonymous" referrerpolicy="no-referrer" />
  <link rel="stylesheet" href="int-image.css">
</head>
<body>
  <script src="ScrollSpy.min.js"></script>
  <script src="highlight-js/highlight.pack.js"></script>
    <header>
      <a href=""><img class="abcri-logo" src="../../Images/Logo_ABCRI.png"></a>
      <a><img class="mngt-logo" src="../../Images/Logo_MNGT.png"></a>
      <h1> <strong>A ABC Research Institute polyglutamine disease database</strong></h1>
    </header>
  <nav>
    <img class="poly-logo" src="../../Images/logo-plyq.png"/>
    <ul>
      <li><a href="../hd">HD</a></li>
      <li><a href="../drpla">DRPLA</a></li>
      <li><a href="../sbma">SBMA</a></li>
    </ul>
      <div class="dropdown">
        <button onclick="myFunction()" class="dropbtn">More <i class="fa-solid fa-caret-down"></i></button>
        <div class="dropdown-content" id="myDropdown">
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
      <div class="dropdown-little">
        <button onclick="myFunctionLittle()" class="dropbtn-little">Other Diseases &nbsp <i class="fa-solid fa-turn-down"></i></button>
        <div class="dropdown-content-little" id="myDropdownLittle">
          <a href="../hd">HD</a>
          <a href="../drpla">DRPLA</a>
          <a href="../sbma">SBMA</a>
          <a href="../sca1">SCA1</a>
          <a href="../sca2">SCA2</a>
          <a href="../sca3">SCA3</a>
          <a href="../sca6">SCA6</a>
          <a href="../sca17">SCA17</a>
        </div>
      </div>
    <a href="../../home" class="return-button"><i class="fa-solid fa-house"></i> Return to Home page </a>
    <a href="../../home" class="return-little"><i class="fa-solid fa-house"></i> Home </a>
  </nav>
  <main>
    <div class="aside-bar-left">
      <h3> Page navigation</h3>
      <div id="indicator"></div>
    </div>
    <div class="text">
    <h1><a href="./"><i class="fa-solid fa-caret-right"></i> &nbspSpinocerebellar Ataxia 7</a></h1>
    <section class="scrollspy" spy-title="Introduction">
      <div class="intro-section">
        <h2> Introduction </h2>
        <p>
          Spinocerebellar ataxia 7 (SCA7) is an inherited disease of the central nervous system. SCA7 is an autosomal dominant cerebellar ataxia type II (ADCA II characterized by progressive ataxia, motor system abnormalities, dysarthria, dysphagia and retinal degeneration leading to progressive blindness. This disease differs from most other forms of SCA in that visual problems, rather than poor coordination, are generally the earliest signs of the disease.
        </p>
        <p>
          SCA7 is inherited in an autosomal dominant manner. Offspring of a heterozygous affected individual have a 50% chance of inheriting an abnormal CAG repeat expansion in ATXN7 <span class="refbig"><a href="#ref-one">[1]</a></span><span class="reflittle"><a href="#ref-one-little">[1]</a></span>.
        </p>
        <p><br></p>
      </div>
    </section>
    <section class="scrollspy" spy-title="First described">
      <div class="firstd-section">
      <h2> First Described</h2>
      <p>
        One subtype of ADCA – first described in 1937 and designated ADCA type II or OPCA type III – was clearly distinguished from all others by the invariable presence of pigmentary retinal dystrophy. This subtype later became known as SCA7 <span class="refbig"><a href="#ref-two">[2]</a></span><span class="reflittle"><a href="#ref-two-little">[2]</a></span>.
      </p>
     </div>
    </section>
    <section class="scrollspy" spy-title="Epidemiology">
      <div class="epi-section">
        <h2> Epidemiology</h2>
        <p>
          The prevalence is fewer than 1:300,000. In several studies, SCA7 represented 2% of all SCAs.
        </p>
        <p>
          SCA7 occurs predominantly in two racial population groups: northern Europeans and Africans. Indeed, SCA7 is the only repeat expansion disease, except for Huntington disease-like 2 (HDL2), with many affected individuals of African racial ancestry. For this reason, a substantial fraction of individuals with SCA7 in the United States are of African racial ancestry. Worldwide, SCA7 is seen in North America, Europe, Eurasia, Australia, South Africa, and South America <span class="refbig"><a href="#ref-three">[3]</a></span><span class="reflittle"><a href="#ref-three-little">[3]</a></span> (<a href="#epi-img">Figure 1</a>).
        </p>
        <p>
          Due to a founder effect in Mexico dating back to the colonial era, a very large concentration of individuals with SCA7 have been ascertained in the state of Veracruz in Mexico, with well over 150 documented affected individuals.
        </p>
        <input type="checkbox" id="zoomCheck">
        <label for="zoomCheck">
          <img id="epi-img" src="../../Images/original images/SCA7/SCA7_epi.png">
        </label>
      <figcaption> <strong>Figure 1:</strong> : Epidemiological features of spinocerebellar ataxia type 7 (SCA7). Prevalence of SCA7 in autosomal dominant cerebellar ataxias, around the world. Created with <a href="https://www.mapchart.net/">MapChart</a>.</figcaption>
        <a class="download-image" href="../../Images/original images/SCA7/SCA7_epi.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Causative gene">
        <div class="gene-section">
          <h2>Causative gene</h2>
          <p>
            ATXN7 is the gene affected in SCA7. It has a size of 140kb with a plus strand orientation. This gene has 13 exons from which 11 are coding exons. According to some authors, the pathological CAG repeats in this gene are found in exon 3 <span class="refbig"><a href="#ref-four">[4]</a></span><span class="reflittle"><a href="#ref-four-little">[4]</a></span> (<a href="#gene-image1">Figure 2</a>).
          </p>
          <p>
            The wild-type alleles of ATXN7 have between 4 and 36 CAG repeats, while SCA7 alleles have typically beyond 36 CAGs and can even reach >460 repeats <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span>. Among CAG/ polyQ disorders, SCA7 CAG repeats show the highest tendency to expand upon transmission, explaining the strong anticipation observed in families.
          </p>
          <p>
            The majority of SCA7 alleles ranges between 36 and 55 CAG repeats and are responsible for the classical adult-onset form, which progresses over several decades <span class="refbig"><a href="#ref-six">[6]</a></span><span class="reflittle"><a href="#ref-six-little">[6]</a></span>. Repeats >70 CAG typically result in juvenile-onset forms with accelerated disease course. The number of CAG repeats also influences the symptoms at onset: large repeat expansions are typically associated with early onset and cause visual loss before cerebellar ataxia, while shorter expansions with later onset cause ataxia symptoms before visual loss
            <span class="refbig"><a href="#ref-seven">[7]</a></span><span class="reflittle"><a href="#ref-seven-little">[7]</a></span> -
            <span class="refbig"><a href="#ref-nine">[9]</a></span><span class="reflittle"><a href="#ref-nine-little">[9]</a></span>. Extremely large CAG expansions (>100 CAG) cause infantile forms with multisystem disorders that lead to death within years or months
            <span class="refbig"><a href="#ref-five">[5]</a></span><span class="reflittle"><a href="#ref-five-little">[5]</a></span>,
            <span class="refbig"><a href="#ref-ten">[10]</a></span><span class="reflittle"><a href="#ref-ten-little">[10]</a></span> -
            <span class="refbig"><a href="#ref-twelve">[12]</a></span><span class="reflittle"><a href="#ref-twelve-little">[12]</a></span>.
          </p>
          <p>
             It is located on chromosome 3 (cytogenic band: 3p14.1, <a href="#gene-image2">Figure 3</a>).
          </p>
          <div class="image-one">
            <img id="gene-image1" src="../../Images/original images/SCA7/ATXN7.png" title="ATXN2 gene">
            <figcaption> <strong>Figure 2:</strong> ATXN7 gene with ranges of the CAG repeats necessary for disease and range in healthy individuals along with information about the total coding exons, chromosome location and size in DNA bases. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA7/ATXN7.png" download> [Fullsize image] </a>
          </div>
          <div class="image-two">
            <img id="gene-image2" src="../../Images/original images/SCA7/chromosome.png" title="ATXN3 gene chromosomal location">
            <figcaption> <strong>Figure 3:</strong> ATXN7 gene chromossomal band localization. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
            <a class="download-image" target="_blank" href="../../Images/original images/SCA7/chromosome.png" download> [Fullsize image] </a>
          </div>
        </div>
    </section>
    <section class="scrollspy" spy-title="Codified protein">
      <div class="protein-section">
        <h2> Codified protein: structure, domains, functions and intracellular localization</h2>
        <h3>Structure and domains</h3>
        <p>
          ATXN7 gene codes for Ataxin-7. Ataxin-7 has a size of 892 aa and a molecular mass of 95 kDa (isoform a). This protein is mostly expressed in the heart, brain, liver, and kidney. Mutation in this protein leads to both olivopontocerebellar atrophy type 3 (OPCA3) and spinocerebellar ataxia type 7 (SCA7). This protein is involved in transcription as an important component of co-activator complexes.
        </p>
        <p>
           An ataxin-7 protein representation is shown in <a href="#protein-image">Figure 4</a> along with <a href="#table">Table 1</a> with information on each important domain (information from <a href="https://www.uniprot.org/">Uniprot.org</a>).
        </p>
        <div class="non-interactive">
          <img id="protein-image" src="../../Images/original images/SCA7/protein.png" title="Ataxin-7 structure">
          <figcaption> <strong>Figure 4: </strong> Ataxin-7 protein representation. Created with <a href="https://biorender.com/"> BioRender.com</a></figcaption>
          <a class="download-image" target="_blank" href="../../Images/original images/SCA7/protein.png" download> [Fullsize image] </a>
        </div>
        <div class="table">
        <table style="width:100%" id="table">
          <caption>Table 1. &nbspAtaxin-7 domains</caption>
          <tr>
            <th>Description</th>
            <th>Position</th>
            <th>Length</th>
          </tr>
          <tr>
            <td>ZfN/ZBD</td>
            <td>126-171</td>
            <td>46</td>
          </tr>
          <tr>
            <td>SCA7 or ATXN7</td>
            <td>334-401</td>
            <td>68</td>
          </tr>
          <tr>
            <td>Conserved</td>
            <td>508-565</td>
            <td>58</td>
          </tr>
        </table>
        <div class="caption-under"> <strong>Table Caption:</strong> Ataxin-7 important domains with respective position within the protein structure and lengths.</div>
      </div>
      <h3>Protein functions and biological role</h3>
      <p>
        Ataxin-7 aids in transcription and stabilization processes:
      </p>
      <ul>
        <li>Acts as component of the STAGA<sup class="hover-text">1</sup><span class="popup-text">Human STAGA Complex Is a Chromatin-Acetylating Transcription Coactivator That Interacts with Pre-mRNA Splicing and DNA Damage-Binding Factors In Vivo</span> transcription coactivator-HAT complex.</li>
        <li>Mediates the interaction of STAGA complex with the CRX and is involved in CRX-dependent gene activation.</li>
        <li>Necessary for microtubule cytoskeleton stabilization <span class="refbig"><a href="#ref-thirteen">[13]</a></span><span class="reflittle"><a href="#ref-thirteen-little">[13]</a></span>.</li>
        <li>Is a subunit of the General control non-depressible 5 (GCN5<sup class="hover-text2">2</sup>)<span class="popup-text2">It acts as both histone acetyltransferase (HAT) and lysine acetyltransferase (KAT).</span> histone acetyltransferase-containing coactivator complexes TFTC/STAGA <span class="refbig"><a href="#ref-fourteen">[14]</a></span><span class="reflittle"><a href="#ref-fourteen-little">[14]</a></span>.</li>
        <li>TFTC/STAGA module acts on H2A and H2B deubiquitination <span class="refbig"><a href="#ref-fifteen">[15]</a></span><span class="reflittle"><a href="#ref-fifteen-little">[15]</a></span>, H3 acetylation
          <span class="refbig"><a href="#ref-sixteen">[16]</a></span><span class="reflittle"><a href="#ref-sixteen-little">[16]</a></span> and is directly involved in nucleus organization
          <span class="refbig"><a href="#ref-seventeen">[17]</a></span><span class="reflittle"><a href="#ref-seventeen-little">[17]</a></span>, and ataxin-7 as part of this module is directly part of this mechanisms.</li>
      </ul>
      <p>
        Problems in ataxin-7 protein were shown to be directly involved in progressive visual impairments <span class="refbig"><a href="#ref-eighteen">[18]</a></span><span class="reflittle"><a href="#ref-eighteen-little">[18]</a></span>. In some organisms it has been demonstrated that mutated ataxin-7 leads to progressively loss of the outer segments (OSs), an essential part for normal visual function
        <span class="refbig"><a href="#ref-nineteen">[19]</a></span><span class="reflittle"><a href="#ref-nineteen-little">[19]</a></span>, it is therefore thought that ataxin-7 is linked to various transcriptional paths responsible for normal eye development and maintenance
        <span class="refbig"><a href="#ref-nineteen">[19]</a></span><span class="reflittle"><a href="#ref-nineteen-little">[19]</a></span>.
      </p>
      <h3> Protein intracellular localization</h3>
      <p>
        Ataxin-7 is found in the nucleus (nucleolus and nucleus matrix) and cytoskeleton. Isoform b can be found in the cytoplasm.
      </p>
      <div class="interactive-image" id="my-interactive-image">
        <img src="../../Images/cell-scheme.jpg" />
      </div>
      <div class="int-caption"> <strong>Figure 5:</strong> Ataxin-7 protein localization.<br>(Refresh this element if changed resolutions &nbsp<a href="javascript:void(0)" onclick="window.location.reload();"><i class="fa-solid fa-arrows-rotate"></i></a>&nbsp)</div>
      </div>
    </section>
    <section class="scrollspy" spy-title="Pathophysiology">
      <div class="patho-section">
        <h2> Pathophysiology</h2>
        <p>
          One major consequence of the polyQ expansion mutation is the intensive intracellular accumulation of mATXN7 in disease tissues (ultimately lead to nuclear inclusions (NIs)).
        </p>
        <p>
          A fragment of about 55 kDa containing the polyQ expansion is detected in protein samples from SCA7 mice and from SCA7 patients <span class="refbig"><a href="#ref-twenty">[20]</a></span><span class="reflittle"><a href="#ref-twenty-little">[20]</a></span> and appears to be the major component of NIs in SCA7 mouse
          <span class="refbig"><a href="#ref-twenty-one">[21]</a></span><span class="reflittle"><a href="#ref-twenty-one-little">[21]</a></span>. Caspase-7 mediated cleavage of mutated ataxin-7 would generate a short fragment containing the amino-terminus with the polyQ tract but without the nuclear export sequence (NES), potentially resulting in accumulation of a mutant ataxin-7 fragment in the nucleus
          <span class="refbig"><a href="#ref-twenty-two">[22]</a></span><span class="reflittle"><a href="#ref-twenty-two-little">[22]</a></span>. These results suggest that the caspase-7 cleavage is a major step in the pathogenesis.
        </p>
        <p>
          The presumed size of the mATXN7 fragment is short enough for passive diffusion through nuclear pore complexes but is retained in the nucleus since it lacks  a NES. It harbors the polyQ expansion and the ZnF domain, but not the ATXN7 domain. With this composition, the mATXN7 fragment may alter the function of Spt-Ada-Gcn5 acetyltransferase (SAGA) complex, either by replacing the full-length protein in the complex or by aggregation and sequestration of SAGA components. Accumulation of the mATXN7 fragment is associated with an increased acetylation at lysine-257 (K257) located close to the caspase-7 cleavage site <span class="refbig"><a href="#ref-twenty-three">[23]</a></span><span class="reflittle"><a href="#ref-twenty-three-little">[23]</a></span>. In the absence of lysine acetylation, the fragment is degraded by autophagy. These results suggest that aberrant K257 acetylation prevents the clearance of the fragment by autophagy, and thereby slows down its turnover. The possibility that transcriptional alterations in SCA7 could result from dysfunction of SAGA acetylation and deubiquitination has been explored in several studies, especially because mATXN7 had been shown to properly incorporate in SAGA
          <span class="refbig"><a href="#ref-twenty-four">[24]</a></span><span class="reflittle"><a href="#ref-twenty-four-little">[24]</a></span>,
          <span class="refbig"><a href="#ref-twenty-five">[25]</a></span><span class="reflittle"><a href="#ref-twenty-five-little">[25]</a></span>.
        </p>
        <p>
          SAGA containing mATXN7 lacks critical subunits and leads to GCN5 or lysine acetyltransferase 2A (KAT2A). With GCN5 dysfunction, photoreceptor-specific genes have hypoacetylation of histone H3 which leads to decreased expression of these same genes <span class="refbig"><a href="#ref-twenty-five">[25]</a></span><span class="reflittle"><a href="#ref-twenty-five-little">[25]</a></span> that eventually meet with the clinical retinal manifestations.
        </p>
        <p>
          K257 residue was shown to be a specific site for SUMOylation<sup class="hover-text3">3</sup> <span class="popup-text3">SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.</span>
          <span class="refbig"><a href="#ref-twenty-six">[26]</a></span><span class="reflittle"><a href="#ref-twenty-six-little">[26]</a></span>. SUMO<sup class="hover-text4">4</sup> <span class="popup-text4">Small Ubiquitin-like Modifier (or SUMO) proteins are a family of small proteins that are covalently attached to and detached from other proteins in cells to modify their function.</span> modification not only decreases the propensity of mATXN7 to aggregate, but also influences the shape and the protein composition of aggregates. With SUMO, aggregates are homogenous, round and strongly stained with SUMO antibodies, while in the absence of SUMO, aggregates are heterogeneous, have a star-like shape and are immunostained for chaperones, proteasomes and activated caspase-3, suggesting that this type of aggregates are associated with cells that undergo cytotoxic.
        </p>
        <img id="patho-img" src="../../Images/original images/SCA7/SCA7.png" title="SCA7 pathogenic mechanisms">
        <div class="caption-patho"> <strong>Figure 6:</strong> SCA7 pathogenesis. A - Intracellular accumulation of mutated ataxin-3 aggregates leads to NIs in more advanced disaese states. B - Accumulation of mutated forms of ataxin-7 leads to increased acetylation at lysine 257 which protects the protein from autophagy. Mutant ataxin-7 is capable of either replacing the entire SAGA complex or sequestering SAGA components compromising functions of the latter. Mutated fragments of ataxin-7 pocess the polyQ tract but they do not contain the NES which leads to increased concentration of polyQ ataxin-7 trapped in the cell nucleus.</div>
        <a class="download-image" target="_blank" href="../../Images/original images/SCA7/SCA7.png" download> [Fullsize image] </a>
      </div>
    </section>
    <section class="scrollspy" spy-title="Clinical manifestations">
      <div class="clinical-section">
        <h2> Clinical manifestations: neuropathology, other signs and symptoms</h2>
        <h3>Neuropathology</h3>
        <p>
          Patients with SCA7 develop atrophy of the cerebellar cortex, dentate nucleus, inferior olive, subthalamic nucleus and olivocerebellar, spinocerebellar and pyramidal tracts. Cerebellar tissue from SCA7 patients has evidence of extensive loss of cerebellar purkinje cells, while only mild changes in the cerebellar granule cell layer are observed. Prominent neuronal loss with gliosis has been noted in the inferior olive <span class="refbig"><a href="#ref-twenty-two">[22]</a></span><span class="reflittle"><a href="#ref-twenty-two-little">[22]</a></span>. Neuronal loss has been reported in brainstem cranial nerve motor nuclei (III, IV, and XII), spinal motor neurons and regions of the basal ganglia, including the substantia nigra
          <span class="refbig"><a href="#ref-twenty-seven">[27]</a></span><span class="reflittle"><a href="#ref-twenty-seven-little">[27]</a></span>. Demyelination of the pyramidal tracts and of the posterior columns of the spinal cord may also occur.
        </p>
        <p>
          Mutant ataxin-7 has been localized to NIs, together with a host of other proteins including ubiquitin-proteasome components <span class="refbig"><a href="#ref-twenty-eight">[28]</a></span><span class="reflittle"><a href="#ref-twenty-eight-little">[28]</a></span>,
          <span class="refbig"><a href="#ref-twenty-nine">[29]</a></span><span class="reflittle"><a href="#ref-twenty-nine-little">[29]</a></span>. While extensive NI formation in SCA7 is present in exquisitely vulnerable neuronal populations, such as the inferior olivary complex and basis pontis, the presence of NIs can extend to other areas of the neuroaxis – e.g. cerebral cortex – that are usually not subject to prominent degeneration. Immunoreactivity patterns varies both between and within distinct brain regions and exhibits age-related changes in some neuronal types – most remarkably cerebellar Purkinje cells and retinal photoreceptors.
        </p>
        <h3> Signs and symptoms</h3>
        <div class="list-flex">
          <div class="column-one">
            <div class="column-one-title">
              <strong>Early symptoms</strong>
            </div>
          <ul>
            <li>Gait ataxia</li>
            <li>Limb ataxia</li>
            <li>Dysarthria</li>
            <li>Slowing of saccades</li>
            <li>Ophthalmoplegia</li>
            <li>Dysphagia</li>
          </ul>
          </div>
          <div class="column-two">
            <div class="column-two-title">
              <strong>SCA7 conspicuous features</strong>
            </div>
          <ul>
            <li>Central vision compromised</li>
            <li>Impairment of color vision</li>
            <li>Degeneration of retina</li>
            <li>Blindness</li>
          </ul>
          </div>
      </div>
      <p>
        In sum, the main features of SCA7 comprise of:
      </p>
        <div class="list-neuronal">
        <ul>
          <li>Progressive changes in vision (which can result in blindness).</li>
          <li>Symptoms of ataxia; </li>
          <li>Slow eye movements </li>
          <li>Mild changes in sensation or reflexes.</li>
        </ul>
      </div>
      </div>
    </section>
    <section class="scrollspy" spy-title="References" id="references">
      <div class="reference-section">
        <h2> References </h2>
        <ol>
          <li><a id="ref-one-little" class="articlebottom">A. R. La Spada, “Spinocerebellar Ataxia Type 7,” GeneReviews®, Jul. 2020, Accessed: Mar. 15, 2022.</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1256/" class="links">[NCBI Books]</a></li>
          <li><a id="ref-two-little" class="articlebottom">C. A. Froment J, Bonnet P, “Heredo-degenerations retinienne et spino-cerebelleuse: variantes ophtalmoscopiques et neurologiques presentees par trois generations successives.,” Med Lyon, pp. 153–163, 1937.</a></li>
          <li><a id="ref-three-little" class="articlebottom">S. S. de O. Scott, J. L. Pedroso, O. G. P. Barsottini, M. C. França-Junior, and P. Braga-Neto, “Natural history and epidemiology of the spinocerebellar ataxias: Insights from the first description to nowadays,” J. Neurol. Sci., vol. 417, Oct. 2020.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X20304196" class="links">[ScienceDirect]</a><a href="https://www.researchgate.net/publication/343491659_Natural_history_and_epidemiology_of_the_spinocerebellar_ataxias_Insights_from_the_first_description_to_nowadays" class="links">[ResearchGate]</a></li>
          <li><a id="ref-four-little" class="articlebottom">C. S. McIntosh, D. Li, S. D. Wilton, and M. T. Aung-Htut, “Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies,” Biomedicines, vol. 9, no. 11, Nov. 2021.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615177/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.mdpi.com/2227-9059/9/11/1499/htm" class="links">[MDPI - Full Text]</a></li>
          <li><a id="ref-five-little" class="articlebottom">B. P. C. Van De Warrenburg et al., “Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype,” J. Neurol., vol. 248, no. 10, pp. 911–914, 2001.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/11697534/" class="links">[PUBMED]</a><a href="https://link.springer.com/article/10.1007/s004150170082" class="links">[Springer]</a></li>
          <li><a id="ref-six-little" class="articlebottom">A. Michalik, J. J. Martin, and C. Van Broeckhoven, “Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy,” Eur. J. Hum. Genet., vol. 12, no. 1, pp. 2–15, Jan. 2004.</a><br><a href="https://www.nature.com/articles/5201108" class="links">[Nature - Full Text]</a></li>
          <li><a id="ref-seven-little" class="articlebottom">G. David et al., “Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7),” Hum. Mol. Genet., vol. 7, no. 2, pp. 165–170, 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/2/165/640510" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-eight-little" class="articlebottom">P. Giunti, G. Stevanin, P. F. Worth, G. David, A. Brice, and N. W. Wood, “Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation.,” Am. J. Hum. Genet., vol. 64, no. 6, p. 1594, 1999.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1377902/" class="links">[PUBMED Central - Full PDF]</a><a href="https://www.cell.com/ajhg/fulltext/S0002-9297(07)63661-1" class="links">[Cell - Full Text]</a></li>
          <li><a id="ref-nine-little" class="articlebottom">J. Johansson, L. Forsgren, O. Sandgren, A. Brice, G. Holmgren, and M. Holmberg, “Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation,” Hum. Mol. Genet., vol. 7, no. 2, pp. 171–176, Feb. 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/2/171/640633" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-ten-little" class="articlebottom">O. Ansorge et al., “Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats,” Ann. Neurol., vol. 56, no. 3, pp. 448–452, Sep. 2004.</a><br><a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.20230" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-eleven-little" class="articlebottom">C. S. Benton, R. De Silva, S. L. Rutledge, S. Bohlega, T. Ashizawa, and H. Y. Zoghbi, “Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype,” Neurology, vol. 51, no. 4, pp. 1081–1086, 1998.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/9781533/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/51/4/1081.abstract" class="links">[Neurology]</a></li>
          <li><a id="ref-twelve-little" class="articlebottom">A. Whitney, M. Lim, D. Kanabar, and J. P. Lin, “Massive SCA7 expansion detected in a 7-month-old male with hypotonia, cardiomegaly, and renal compromise,” Dev. Med. Child Neurol., vol. 49, no. 2, pp. 140–143, Feb. 2007.</a><br><a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1469-8749.2007.00140.x" class="links">[Wiley Online Library]</a></li>
          <li><a id="ref-thirteen-little" class="articlebottom">Y. Nakamura et al., “Ataxin-7 associates with microtubules and stabilizes the cytoskeletal network,” Hum. Mol. Genet., vol. 21, no. 5, pp. 1099–1110, Mar. 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277310/" class="links">[PUBMED Central - Full Text]</a><a href="https://academic.oup.com/hmg/article/21/5/1099/585172" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-fourteen-little" class="articlebottom">D. Helmlinger et al., “Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction,” PLoS Biol., vol. 4, no. 3, pp. 0432–0445, Mar. 2006.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382020/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.0040067" class="links">[PLOS - Full Text]</a></li>
          <li><a id="ref-fifteen-little" class="articlebottom">Y. Zhao et al., “A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing,” Mol. Cell, vol. 29, no. 1, pp. 92–101, Jan. 2008.</a><br><a href="https://www.cell.com/molecular-cell/fulltext/S1097-2765(07)00885-4" class="links">[Cell - Full Text]</a></li>
          <li><a id="ref-sixteen-little" class="articlebottom">M. Brand, K. Yamamoto, A. Staub, and L. Tora, “Identification of TATA-binding protein-free TAFII-containing complex subunits suggests a role in nucleosome acetylation and signal transduction,” J. Biol. Chem., vol. 274, no. 26, pp. 18285–18289, Jun. 1999.</a><br><a href="https://www.jbc.org/article/S0021-9258(19)87157-0/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a id="ref-seventeen-little" class="articlebottom">M. D. Kaytor, L. A. Duvick, P. J. Skinner, M. D. Koob, L. P. W. Ranum, and H. T. Orr, “Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7,” Hum. Mol. Genet., vol. 8, no. 9, pp. 1657–1664, 1999.</a><br><a href="https://academic.oup.com/hmg/article/8/9/1657/815266" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-eighteen-little" class="articlebottom">A. Campos-Romo et al., “Ophthalmic features of spinocerebellar ataxia type 7,” Eye 2018 321, vol. 32, no. 1, pp. 120–127, Aug. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770701/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.nature.com/articles/eye2017135" class="links">[Nature - Full Text]</a></li>
          <li><a id="ref-nineteen-little" class="articlebottom">S. Carrillo-Rosas, C. Weber, L. Fievet, N. Messaddeq, A. Karam, and Y. Trottier, “Loss of zebrafish Ataxin-7, a SAGA subunit responsible for SCA7 retinopathy, causes ocular coloboma and malformation of photoreceptors,” Hum. Mol. Genet., vol. 28, no. 6, pp. 912–927, Mar. 2019.</a><br><a href="https://academic.oup.com/hmg/article/28/6/912/5185123" class="links">[Oxford Academic- Full Text]</a></li>
          <li><a id="ref-twenty-little" class="articlebottom">G. A. Garden et al., “Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice,” J. Neurosci., vol. 22, no. 12, pp. 4897–4905, Jun. 2002.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757746/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/22/12/4897.long" class="links">[JNeurosci - Full Text]</a></li>
          <li><a id="ref-twenty-one-little" class="articlebottom">G. Yvert, K. S. Lindenberg, S. Picaud, G. B. Landwehrmeyer, J. A. Sahel, and J. L. Mandel, “Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice,” Hum. Mol. Genet., vol. 9, no. 17, pp. 2491–2506, Oct. 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/17/2491/619685" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-two-little" class="articlebottom">G. A. Garden and A. R. La Spada, “Molecular Pathogenesis and Cellular Pathology of Spinocerebellar Ataxia Type 7 Neurodegeneration,” Cerebellum, vol. 7, no. 2, p. 138, Jun. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195584/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a id="ref-twenty-three-little" class="articlebottom">S. Mookerjee et al., “Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment,” J. Neurosci., vol. 29, no. 48, pp. 15134–15144, Dec. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907146/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/29/48/15134" class="links">[JNeurosci - Full Text]</a></li>
          <li><a id="ref-twenty-four-little" class="articlebottom">D. Helmlinger et al., “Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes,” Hum. Mol. Genet., vol. 13, no. 12, pp. 1257–1265, Jun. 2004.</a><br><a href="https://academic.oup.com/hmg/article/13/12/1257/587905" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-five-little" class="articlebottom">V. B. Palhan et al., “Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration,” Proc. Natl. Acad. Sci. U. S. A., vol. 102, no. 24, pp. 8472–8477, Jun. 2005.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1150862/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.pnas.org/doi/10.1073/pnas.0503505102" class="links">[PNAS - Full Text]</a></li>
          <li><a id="ref-twenty-six-little" class="articlebottom">A. Janer et al., “SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7,” Hum. Mol. Genet., vol. 19, no. 1, pp. 181–195, Oct. 2010.</a><br><a href="https://academic.oup.com/hmg/article/19/1/181/600092" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-seven-little" class="articlebottom">J. J. Martin, N. Van Regemorter, J. Del-Favero, A. Löfgren, and C. Van Broeckhoven, “Spinocerebellar ataxia type 7 (SCA7) - correlations between phenotype and genotype in one large Belgian family,” J. Neurol. Sci., vol. 168, no. 1, pp. 37–46, Sep. 1999.</a><br><a href="https://www.jns-journal.com/article/S0022-510X(99)00176-8/fulltext" class="links">[JNS]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X99001768" class="links">[ScienceDirect]</a></li>
          <li><a id="ref-twenty-eight-little" class="articlebottom">M. Holmberg et al., “Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions,” Hum. Mol. Genet., vol. 7, no. 5, pp. 913–918, May 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/5/913/759556" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a id="ref-twenty-nine-little" class="articlebottom">J. Takahashi et al., “Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content,” Brain, vol. 125, no. Pt 7, pp. 1534–1543, 2002.</a><br><a href="https://academic.oup.com/brain/article/125/7/1534/409332" class="links">[Oxford Academic - Full Text ]</a></li>
        </ol>
      </div>
    </section>
    </div>
    <div class="aside-bar-right" id="bar-right">
      <div class="ref-side-bar">
        <h3><i class="fa-solid fa-link"></i> References</h3>
        <ul>
          <li><a href="" id="ref-one" class="articlefocus">1. &nbspA. R. La Spada, “Spinocerebellar Ataxia Type 7,” GeneReviews®, Jul. 2020, Accessed: Mar. 15, 2022.</a><br><a href="https://www.ncbi.nlm.nih.gov/books/NBK1256/" class="links">[NCBI Books]</a></li>
          <li><a href="" id="ref-two" class="articlefocus">2. &nbspC. A. Froment J, Bonnet P, “Heredo-degenerations retinienne et spino-cerebelleuse: variantes ophtalmoscopiques et neurologiques presentees par trois generations successives.,” Med Lyon, pp. 153–163, 1937.</a></li>
          <li><a href="" id="ref-three" class="articlefocus">3. &nbspS. S. de O. Scott, J. L. Pedroso, O. G. P. Barsottini, M. C. França-Junior, and P. Braga-Neto, “Natural history and epidemiology of the spinocerebellar ataxias: Insights from the first description to nowadays,” J. Neurol. Sci., vol. 417, Oct. 2020.</a><br><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X20304196" class="links">[ScienceDirect]</a><a href="https://www.researchgate.net/publication/343491659_Natural_history_and_epidemiology_of_the_spinocerebellar_ataxias_Insights_from_the_first_description_to_nowadays" class="links">[ResearchGate]</a></li>
          <li><a href="" id="ref-four" class="articlefocus">4. &nbspC. S. McIntosh, D. Li, S. D. Wilton, and M. T. Aung-Htut, “Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies,” Biomedicines, vol. 9, no. 11, Nov. 2021.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615177/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.mdpi.com/2227-9059/9/11/1499/htm" class="links">[MDPI - Full Text]</a></li>
          <li><a href="" id="ref-five" class="articlefocus">5. &nbspB. P. C. Van De Warrenburg et al., “Striking anticipation in spinocerebellar ataxia type 7: the infantile phenotype,” J. Neurol., vol. 248, no. 10, pp. 911–914, 2001.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/11697534/" class="links">[PUBMED]</a><a href="https://link.springer.com/article/10.1007/s004150170082" class="links">[Springer]</a></li>
          <li><a href="" id="ref-six" class="articlefocus">6. &nbspA. Michalik, J. J. Martin, and C. Van Broeckhoven, “Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy,” Eur. J. Hum. Genet., vol. 12, no. 1, pp. 2–15, Jan. 2004.</a><br><a href="https://www.nature.com/articles/5201108" class="links">[Nature - Full Text]</a></li>
          <li><a href="" id="ref-seven" class="articlefocus">7. &nbspG. David et al., “Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7),” Hum. Mol. Genet., vol. 7, no. 2, pp. 165–170, 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/2/165/640510" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-eight" class="articlefocus">8. &nbspP. Giunti, G. Stevanin, P. F. Worth, G. David, A. Brice, and N. W. Wood, “Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation.,” Am. J. Hum. Genet., vol. 64, no. 6, p. 1594, 1999.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1377902/" class="links">[PUBMED Central - Full PDF]</a><a href="https://www.cell.com/ajhg/fulltext/S0002-9297(07)63661-1" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-nine" class="articlefocus">9. &nbspJ. Johansson, L. Forsgren, O. Sandgren, A. Brice, G. Holmgren, and M. Holmberg, “Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation,” Hum. Mol. Genet., vol. 7, no. 2, pp. 171–176, Feb. 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/2/171/640633" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-ten" class="articlefocus">10. &nbspO. Ansorge et al., “Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats,” Ann. Neurol., vol. 56, no. 3, pp. 448–452, Sep. 2004.</a><br><a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.20230" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-eleven" class="articlefocus">11. &nbspC. S. Benton, R. De Silva, S. L. Rutledge, S. Bohlega, T. Ashizawa, and H. Y. Zoghbi, “Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype,” Neurology, vol. 51, no. 4, pp. 1081–1086, 1998.</a><br><a href="https://pubmed.ncbi.nlm.nih.gov/9781533/" class="links">[PUBMED]</a><a href="https://n.neurology.org/content/51/4/1081.abstract" class="links">[Neurology]</a></li>
          <li><a href="" id="ref-twelve" class="articlefocus">12. &nbspA. Whitney, M. Lim, D. Kanabar, and J. P. Lin, “Massive SCA7 expansion detected in a 7-month-old male with hypotonia, cardiomegaly, and renal compromise,” Dev. Med. Child Neurol., vol. 49, no. 2, pp. 140–143, Feb. 2007.</a><br><a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1469-8749.2007.00140.x" class="links">[Wiley Online Library]</a></li>
          <li><a href="" id="ref-thirteen" class="articlefocus">13. &nbspY. Nakamura et al., “Ataxin-7 associates with microtubules and stabilizes the cytoskeletal network,” Hum. Mol. Genet., vol. 21, no. 5, pp. 1099–1110, Mar. 2012.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277310/" class="links">[PUBMED Central - Full Text]</a><a href="https://academic.oup.com/hmg/article/21/5/1099/585172" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-fourteen" class="articlefocus">14. &nbspD. Helmlinger et al., “Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction,” PLoS Biol., vol. 4, no. 3, pp. 0432–0445, Mar. 2006.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382020/" class="links">[PUBMED Central - Full Text]</a><a href="https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.0040067" class="links">[PLOS - Full Text]</a></li>
          <li><a href="" id="ref-fifteen" class="articlefocus">15. &nbspY. Zhao et al., “A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing,” Mol. Cell, vol. 29, no. 1, pp. 92–101, Jan. 2008.</a><br><a href="https://www.cell.com/molecular-cell/fulltext/S1097-2765(07)00885-4" class="links">[Cell - Full Text]</a></li>
          <li><a href="" id="ref-sixteen" class="articlefocus">16. &nbspM. Brand, K. Yamamoto, A. Staub, and L. Tora, “Identification of TATA-binding protein-free TAFII-containing complex subunits suggests a role in nucleosome acetylation and signal transduction,” J. Biol. Chem., vol. 274, no. 26, pp. 18285–18289, Jun. 1999.</a><br><a href="https://www.jbc.org/article/S0021-9258(19)87157-0/fulltext" class="links">[JBC - Full Text]</a></li>
          <li><a href="" id="ref-seventeen" class="articlefocus">17. &nbspM. D. Kaytor, L. A. Duvick, P. J. Skinner, M. D. Koob, L. P. W. Ranum, and H. T. Orr, “Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7,” Hum. Mol. Genet., vol. 8, no. 9, pp. 1657–1664, 1999.</a><br><a href="https://academic.oup.com/hmg/article/8/9/1657/815266" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-eighteen" class="articlefocus">18. &nbspA. Campos-Romo et al., “Ophthalmic features of spinocerebellar ataxia type 7,” Eye 2018 321, vol. 32, no. 1, pp. 120–127, Aug. 2017.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770701/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.nature.com/articles/eye2017135" class="links">[Nature - Full Text]</a></li>
          <li><a href="" id="ref-nineteen" class="articlefocus">19. &nbspS. Carrillo-Rosas, C. Weber, L. Fievet, N. Messaddeq, A. Karam, and Y. Trottier, “Loss of zebrafish Ataxin-7, a SAGA subunit responsible for SCA7 retinopathy, causes ocular coloboma and malformation of photoreceptors,” Hum. Mol. Genet., vol. 28, no. 6, pp. 912–927, Mar. 2019.</a><br><a href="https://academic.oup.com/hmg/article/28/6/912/5185123" class="links">[Oxford Academic- Full Text]</a></li>
          <li><a href="" id="ref-twenty" class="articlefocus">20. &nbspG. A. Garden et al., “Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice,” J. Neurosci., vol. 22, no. 12, pp. 4897–4905, Jun. 2002.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757746/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/22/12/4897.long" class="links">[JNeurosci - Full Text]</a></li>
          <li><a href="" id="ref-twenty-one" class="articlefocus">21. &nbspG. Yvert, K. S. Lindenberg, S. Picaud, G. B. Landwehrmeyer, J. A. Sahel, and J. L. Mandel, “Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice,” Hum. Mol. Genet., vol. 9, no. 17, pp. 2491–2506, Oct. 2000.</a><br><a href="https://academic.oup.com/hmg/article/9/17/2491/619685" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-two" class="articlefocus">22. &nbspG. A. Garden and A. R. La Spada, “Molecular Pathogenesis and Cellular Pathology of Spinocerebellar Ataxia Type 7 Neurodegeneration,” Cerebellum, vol. 7, no. 2, p. 138, Jun. 2008.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195584/" class="links">[PUBMED Central - Full Text]</a></li>
          <li><a href="" id="ref-twenty-three" class="articlefocus">23. &nbspS. Mookerjee et al., “Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment,” J. Neurosci., vol. 29, no. 48, pp. 15134–15144, Dec. 2009.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907146/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.jneurosci.org/content/29/48/15134" class="links">[JNeurosci - Full Text]</a></li>
          <li><a href="" id="ref-twenty-four" class="articlefocus">24. &nbspD. Helmlinger et al., “Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes,” Hum. Mol. Genet., vol. 13, no. 12, pp. 1257–1265, Jun. 2004.</a><br><a href="https://academic.oup.com/hmg/article/13/12/1257/587905" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-five" class="articlefocus">25. &nbspV. B. Palhan et al., “Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration,” Proc. Natl. Acad. Sci. U. S. A., vol. 102, no. 24, pp. 8472–8477, Jun. 2005.</a><br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1150862/" class="links">[PUBMED Central - Full Text]</a><a href="https://www.pnas.org/doi/10.1073/pnas.0503505102" class="links">[PNAS - Full Text]</a></li>
          <li><a href="" id="ref-twenty-six" class="articlefocus">26. &nbspA. Janer et al., “SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7,” Hum. Mol. Genet., vol. 19, no. 1, pp. 181–195, Oct. 2010.</a><br><a href="https://academic.oup.com/hmg/article/19/1/181/600092" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-seven" class="articlefocus">27. &nbspJ. J. Martin, N. Van Regemorter, J. Del-Favero, A. Löfgren, and C. Van Broeckhoven, “Spinocerebellar ataxia type 7 (SCA7) - correlations between phenotype and genotype in one large Belgian family,” J. Neurol. Sci., vol. 168, no. 1, pp. 37–46, Sep. 1999.</a><br><a href="https://www.jns-journal.com/article/S0022-510X(99)00176-8/fulltext" class="links">[JNS]</a><a href="https://www.sciencedirect.com/science/article/abs/pii/S0022510X99001768" class="links">[ScienceDirect]</a></li>
          <li><a href="" id="ref-twenty-eight" class="articlefocus">28. &nbspM. Holmberg et al., “Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions,” Hum. Mol. Genet., vol. 7, no. 5, pp. 913–918, May 1998.</a><br><a href="https://academic.oup.com/hmg/article/7/5/913/759556" class="links">[Oxford Academic - Full Text]</a></li>
          <li><a href="" id="ref-twenty-nine" class="articlefocus">29. &nbspJ. Takahashi et al., “Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content,” Brain, vol. 125, no. Pt 7, pp. 1534–1543, 2002.</a><br><a href="https://academic.oup.com/brain/article/125/7/1534/409332" class="links">[Oxford Academic - Full Text ]</a></li>
        </ul>
      </div>
    </div>
  </main>
  <footer id=footer>
    <div class="collumns">
      <div class="first-third">
        <ul>
          <li><a href="../../">Landing Page</a></li>
          <li><a href="https://abcri.pt/">ABC-RI</a></li>
          <li><a href="https://abcri.pt/research-groups/clevio-nobrega/#menu">MNGT group</a></li>
          <li><a href="https://abcri.pt/news/">ABC-RI News</a></li>
        </ul>
      </div>
      <div class="second-third">
        <ul>
          <li><a href="../../authors">Authors</a></li>
          <li><a href="https://www.ualg.pt/">UAlg</a></li>
          <li><a href="https://fmcb.ualg.pt/en">UAlg - FMCB</a></li>
          <li><a href="https://fmcb.ualg.pt/en/master-biomedical-sciences">Masters degree</a></li>
        </ul>
      </div>
      <div class="third-third">
        <ul>
          <li><a href="../../contact">Contact</a></li>
          <li><a href="../../objectives">Objectives</a></li>
          <li><a href="../../appreciation">Appreciation</a></li>
        </ul>
      </div>
    </div>
    <svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="200.000000pt" height="200.000000pt" viewBox="0 0 200.000000 200.000000" preserveAspectRatio="xMidYMid meet">
<metadata>
Created by potrace 1.10, written by Peter Selinger 2001-2011
</metadata>
<g transform="translate(0.000000,200.000000) scale(0.100000,-0.100000)" fill="#3d85c6" stroke="none">
<path d="M1514 1622 c-11 -10 -31 -22 -44 -25 -38 -10 -45 -17 -84 -82 -40 -67 -44 -94 -20 -135 18 -29 101 -80 132 -80 10 0 23 -5 29 -11 6 -6 26 -14 43 -18 24 -4 38 -16 51 -40 10 -19 23 -39 28 -44 14 -14 61 19 61 43 0 12 10 25 23 30 36 15 78 65 89 107 20 79 20 89 -8 152 -25 55 -33 64 -83 90 -72 36 -185 42 -217 13z m76 -27 c-10 -12 -10 -19 -2 -27 9 -9 18 -4 37 16 14 15 28 25 33 23 4 -2 25 -12 47 -22 40 -18 75 -43 75 -54 0 -9 -67 -7 -76 2 -12 12 -44 8 -44 -5 0 -20 48 -38 81 -31 49 9 81 -33 63 -81 -7 -19 -36 -21 -65 -3 -17 9 -23 9 -26 0 -3 -8 -14 -11 -28 -7 -12 3 -26 1 -30 -5 -3 -6 -17 -8 -31 -5 -13 3 -24 2 -24 -4 0 -19 -33 -22 -57 -6 -35 22 -52 3 -23 -24 21 -20 21 -20 2 -26 -23 -8 -117 37 -126 60 -9 24 -7 74 3 74 5 0 11 -7 15 -15 9 -26 48 -17 77 18 21 24 28 28 29 15 0 -24 22 -23 38 2 7 11 21 20 31 20 11 0 22 4 26 9 10 17 -15 23 -68 16 -38 -6 -58 -15 -78 -37 -25 -26 -29 -27 -37 -11 -19 32 20 83 64 83 8 0 23 9 34 20 11 11 32 20 46 20 23 0 25 -2 14 -15z m179 -224 l34 -1 -23 -25 c-25 -26 -59 -32 -91 -15 -15 8 -24 6 -41 -10 -13 -11 -35 -20 -54 -20 -60 0 -53 30 11 50 22 7 46 15 53 19 8 3 28 5 45 5 18 -1 47 -2 66 -3z m-34 -81 c-3 -5 -12 -10 -20 -10 -8 0 -17 5 -20 10 -4 6 5 10 20 10 15 0 24 -4 20 -10z m-61 -22 c14 -55 0 -64 -26 -19 -12 22 -13 31 -5 35 21 8 25 6 31 -16z"/>
<path d="M72 1198 c-23 -23 -14 -59 18 -71 l30 -11 0 -163 c0 -150 -1 -163 -18 -163 -37 0 -57 -51 -30 -78 15 -15 100 -15 152 -1 60 16 158 119 182 189 32 94 68 153 113 187 23 18 48 33 54 33 9 0 12 -46 12 -165 0 -91 -1 -165 -2 -165 -1 0 -13 5 -27 11 -25 12 -25 14 -28 142 l-3 130 -29 -41 c-25 -37 -28 -48 -24 -102 4 -63 -4 -78 -19 -34 -9 26 -10 26 -36 -27 l-26 -54 31 -33 c81 -83 206 -106 306 -56 81 40 129 104 177 238 20 54 73 119 117 142 l28 15 0 -166 0 -165 -22 11 c-22 10 -23 13 -20 139 3 142 -1 151 -48 88 -19 -26 -22 -40 -18 -94 2 -35 3 -64 1 -64 -1 0 -8 12 -16 26 l-14 26 -26 -53 -26 -54 32 -34 c92 -97 257 -108 353 -24 44 39 93 115 114 177 27 82 69 140 120 166 l40 20 0 -164 0 -165 -22 8 c-22 8 -23 15 -28 137 l-5 128 -29 -34 c-26 -31 -28 -39 -24 -97 4 -66 -4 -82 -19 -37 -9 26 -10 26 -36 -27 l-26 -54 32 -33 c52 -55 116 -82 191 -82 56 0 67 3 76 21 9 16 8 26 -5 45 -8 13 -22 24 -30 24 -13 0 -15 26 -15 164 0 152 1 164 19 169 31 8 43 40 25 65 -13 18 -25 22 -72 22 -131 0 -232 -90 -286 -256 -19 -57 -73 -127 -117 -149 -15 -8 -30 -15 -34 -15 -3 0 -5 74 -5 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -22 19 -143 l0 -132 28 28 c23 24 28 37 32 105 6 73 6 75 18 48 l13 -30 25 54 25 53 -38 39 c-54 55 -107 78 -181 78 -112 0 -206 -69 -259 -188 -13 -31 -34 -78 -45 -104 -21 -48 -51 -82 -100 -113 l-28 -17 0 166 c0 164 0 167 20 156 18 -10 20 -21 20 -143 l1 -132 36 39 c35 38 35 39 29 102 -7 69 -2 81 15 37 l11 -28 23 45 c32 61 31 73 -12 110 -114 100 -276 92 -375 -18 -42 -47 -63 -83 -89 -159 -10 -30 -28 -67 -40 -84 -22 -31 -94 -89 -111 -89 -4 0 -8 74 -8 165 0 91 3 165 6 165 3 0 14 -5 25 -10 17 -10 19 -23 19 -143 l1 -132 29 34 c25 30 30 44 32 105 3 68 4 70 17 44 l14 -27 23 50 c22 46 22 52 8 74 -17 27 -76 69 -117 84 -38 15 -140 14 -155 -1z m153 -22 c19 -8 51 -27 70 -42 50 -38 44 -69 -17 -88 -15 -4 -18 -17 -18 -71 0 -37 -4 -64 -9 -61 -5 3 -9 41 -9 83 0 43 -1 86 -1 95 -1 25 -58 53 -77 37 -19 -15 -21 -318 -2 -337 24 -24 57 -12 107 36 37 36 56 66 81 130 18 46 46 101 62 123 36 49 111 106 117 87 2 -7 10 -21 19 -30 14 -16 13 -18 -6 -18 -48 0 -103 -73 -151 -199 -26 -69 -84 -143 -133 -171 -48 -27 -161 -40 -173 -20 -5 9 3 22 24 39 l31 26 0 160 0 160 -31 26 c-19 15 -29 31 -25 37 10 17 100 15 141 -2z m487 -12 c18 -9 47 -30 65 -47 26 -24 30 -34 22 -49 -5 -10 -21 -18 -34 -18 -27 0 -33 -13 -38 -95 -2 -27 -4 -8 -5 44 -2 82 -5 98 -24 118 -25 27 -41 29 -62 7 -23 -23 -23 -315 0 -338 20 -20 20 -20 69 8 51 30 85 78 124 174 37 92 62 129 115 168 54 41 108 58 162 50 86 -11 172 -74 159 -116 -4 -13 -13 -20 -24 -18 -10 2 -25 -3 -34 -11 -15 -12 -17 -10 -17 22 0 27 -7 41 -27 57 -32 25 -54 23 -68 -6 -10 -21 -10 -21 -28 3 -22 28 -45 24 -91 -14 -46 -38 -81 -93 -106 -164 -41 -119 -116 -192 -215 -210 -87 -16 -126 9 -70 45 25 16 25 17 25 180 l0 164 -27 20 c-18 13 -24 24 -20 36 6 15 16 17 62 12 30 -3 70 -13 87 -22z m898 10 c2 -3 -9 -16 -25 -28 -30 -23 -30 -26 -33 -127 -2 -57 -5 -106 -8 -108 -2 -2 -4 43 -4 101 0 123 -9 139 -60 118 -46 -19 -112 -99 -134 -161 -25 -72 -68 -148 -103 -181 -85 -81 -235 -83 -312 -4 -25 25 -31 39 -26 55 3 12 14 21 24 21 28 0 41 21 43 70 1 26 4 11 7 -39 6 -77 8 -86 33 -104 27 -20 28 -20 48 -2 18 16 20 32 22 159 l2 141 6 -149 c6 -178 11 -185 85 -142 52 31 95 91 121 170 49 145 154 231 269 219 22 -3 42 -7 45 -9z m-1072 -380 c20 -10 21 -13 7 -24 -8 -7 -15 -19 -15 -27 0 -11 -6 -11 -30 4 -17 10 -42 30 -56 44 -22 23 -23 29 -13 52 7 15 17 23 25 20 28 -11 44 18 46 81 1 46 3 37 7 -39 6 -91 8 -100 29 -111z m912 44 c0 -55 51 -88 80 -53 11 13 16 12 41 -8 50 -39 30 -62 -44 -51 -51 8 -102 34 -139 69 -23 21 -26 29 -16 44 6 11 19 16 29 14 11 -3 21 1 25 11 9 24 24 9 24 -26z"/>
<path d="M470 550 c0 -65 3 -90 13 -90 9 0 11 23 9 90 -2 49 -8 90 -13 90 -5 0 -9 -40 -9 -90z"/>
<path d="M1090 551 l0 -89 33 1 c31 2 32 3 35 55 3 56 -10 85 -34 75 -10 -4 -14 2 -14 21 0 14 -4 26 -10 26 -6 0 -10 -36 -10 -89z m48 -27 c-2 -22 -7 -39 -13 -39 -12 0 -19 60 -10 83 10 28 27 -3 23 -44z"/>
<path d="M280 545 c0 -69 3 -85 15 -85 9 0 15 9 15 25 0 15 6 25 15 25 19 0 35 31 35 69 0 32 -22 51 -59 51 -20 0 -21 -6 -21 -85z m50 19 c0 -19 -4 -34 -10 -34 -5 0 -10 18 -10 41 0 24 4 38 10 34 6 -3 10 -22 10 -41z"/>
<path d="M612 618 c-7 -7 -12 -38 -12 -70 0 -45 5 -66 22 -88 21 -29 58 -41 58 -20 0 6 -7 10 -17 10 -15 0 -15 1 0 18 12 13 17 37 17 78 0 61 -11 84 -40 84 -9 0 -21 -5 -28 -12z m46 -85 c-5 -72 -28 -68 -28 5 0 32 3 62 7 66 13 13 24 -24 21 -71z"/>
<path d="M750 545 c0 -83 0 -85 24 -85 39 0 56 25 56 84 0 58 -19 86 -58 86 -21 0 -22 -4 -22 -85z m45 0 c0 -38 -4 -60 -12 -62 -10 -4 -13 13 -13 62 0 49 3 66 13 63 8 -3 12 -25 12 -63z"/>
<path d="M939 608 c-3 -53 3 -134 11 -142 5 -5 17 -5 27 -1 17 8 17 8 1 12 -25 6 -26 91 -2 100 15 6 15 7 -1 19 -9 7 -14 17 -10 23 3 6 -1 11 -9 11 -10 0 -17 -9 -17 -22z"/>
<path d="M392 591 c-19 -11 -27 -83 -13 -110 15 -26 47 -27 61 -2 15 29 12 87 -6 105 -18 18 -24 19 -42 7z m28 -61 c0 -27 -4 -50 -10 -50 -5 0 -10 23 -10 50 0 28 5 50 10 50 6 0 10 -22 10 -50z"/>
<path d="M510 588 c0 -7 7 -40 15 -73 12 -52 12 -61 0 -71 -20 -15 -19 -24 5 -24 19 0 28 22 45 110 4 19 9 43 11 53 4 11 0 17 -10 17 -11 0 -16 -9 -16 -29 0 -16 -3 -38 -7 -48 -6 -13 -9 -6 -13 26 -3 25 -11 46 -17 49 -7 2 -13 -2 -13 -10z"/>
<path d="M852 588 c-13 -13 -16 -38 -6 -38 4 0 13 8 20 18 12 16 13 16 20 -2 5 -13 3 -21 -4 -24 -24 -8 -43 -35 -40 -56 2 -16 11 -21 36 -23 l32 -1 0 63 c0 48 -4 64 -16 69 -22 8 -28 8 -42 -6z m38 -88 c0 -19 -11 -26 -23 -14 -8 8 3 34 14 34 5 0 9 -9 9 -20z"/>
<path d="M1006 584 c-20 -20 -20 -34 -1 -34 8 0 15 7 15 15 0 8 5 15 10 15 19 0 10 -31 -16 -54 -37 -31 -26 -66 20 -66 l33 0 -4 58 c-3 31 -6 63 -8 70 -6 17 -30 15 -49 -4z m34 -84 c0 -11 -4 -20 -10 -20 -5 0 -10 9 -10 20 0 11 5 20 10 20 6 0 10 -9 10 -20z"/>
<path d="M1193 593 c-13 -5 -18 -43 -7 -43 4 0 13 8 20 18 12 16 13 16 14 0 0 -9 -11 -29 -25 -42 -33 -33 -21 -65 25 -64 30 1 30 2 30 58 0 69 -16 90 -57 73z m23 -110 c-11 -11 -19 6 -11 24 8 17 8 17 12 0 3 -10 2 -21 -1 -24z"/>
<path d="M1271 581 c-8 -15 -5 -27 15 -56 25 -37 26 -65 0 -30 -9 13 -15 15 -20 6 -11 -17 14 -42 38 -39 29 4 32 35 7 69 -12 15 -21 34 -21 41 1 8 5 7 14 -4 17 -23 26 -23 26 1 0 17 -18 31 -40 31 -5 0 -14 -9 -19 -19z"/>
<path d="M1362 588 c-7 -7 -12 -36 -12 -65 0 -57 17 -76 48 -56 22 13 27 33 8 33 -9 0 -16 -4 -16 -10 0 -5 -4 -10 -10 -10 -5 0 -10 9 -10 20 0 15 7 20 25 20 21 0 25 5 25 28 0 29 -16 52 -35 52 -6 0 -16 -5 -23 -12z m38 -40 c0 -5 -7 -8 -15 -8 -15 0 -20 21 -8 33 7 7 23 -11 23 -25z"/>
</g>
</svg>
    <p> &copyPolyQ Database. All rights reserved 2021-2022. Authors mentioned and database creators all accounted for.</p>
    <div class="logos">
      <a class="logo-one" href=""> <img src="../../Images/Logo_ABCRI.png" alt=""></a>
      <a class="logo-two" href=""> <img src="../../Images/Logo_MNGT.png" alt=""></a>
      <a class="logo-three" href=""> <img src="../../Images/fmcb-mod.png" alt=""></a>
    </div>
  </footer>
  <script src="../../Scripts/jquery-3.6.0.min.js"></script>
  <script type="text/javascript" src="https://cdn.jsdelivr.net/npm/interactiveimagejs@2.7.1/dist/interactive-image.min.js"></script>
  <script src="../../Scripts/Image-Int-Scripts/image-int-sca7.js"></script>
  <script>
            var indicator = document.getElementById('indicator');

            var spy = new ScrollSpy(
                {
                    contexts_class: 'scrollspy'
                }
            );

            spy.Indicator({
                element: indicator
            });
</script>
<script>
/* When the user clicks on the button,
toggle between hiding and showing the dropdown content */
function myFunction() {
  document.getElementById("myDropdown").classList.toggle("show");
}

function myFunctionLittle() {
  document.getElementById("myDropdownLittle").classList.toggle("show");
}

// Close the dropdown if the user clicks outside of it
window.onclick = function(event) {
  if (!event.target.matches('.dropbtn')) {
    var dropdowns = document.getElementsByClassName("dropdown-content");
    var i;
    for (i = 0; i < dropdowns.length; i++) {
      var openDropdown = dropdowns[i];
      if (openDropdown.classList.contains('show')) {
        openDropdown.classList.remove('show');
      }
    }
  }
  if (!event.target.matches('.dropbtn-little')){
    var dropLittle = document.getElementsByClassName("dropdown-content-little");
    var r;
    for (r = 0; r < dropLittle.length; r++) {
      var openDropLittle = dropLittle[r];
      if (openDropLittle.classList.contains('show')) {
        openDropLittle.classList.remove('show');
      }
    }
  }
}

</script>
<script>


$(document).scroll(function() {
    checkOffset();
});

function checkOffset() {
    if($('#bar-right').offset().top + $('#bar-right').height() >= $('#references').offset().top + 200)
          $('#bar-right').hide(800);
    if($(document).scrollTop() + window.innerHeight < $('#references').offset().top + 200)
          $('#bar-right').show(800); // restore when you scroll up
}
</script>
<script>

function reload(){
  var imageInt = document.getElementById("my-interactive-image");
  var imageContent = imageInt.innerHTML;
  imageInt.innerHTML = imageContent;
}

</script>


</body>


</html>
